The U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access.
Register now for FREE unlimited access to Reuters.comJan 11 - The U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc'sBiogen shares were down 7.3% at $224 in extended trading on Tuesday.
Biogen said in a statement that the decision to require the trial "will exclude almost all patients who may benefit." Many experts have questioned the U.S. Food and Drug Administration's rationale for Aduhelm's approval without more definitive proof of benefit, and doctors have held back on prescribing it.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Les mer »
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Les mer »
Medicare Told to Reassess Premium Hike for Alzheimer's DrugU.S. health secretary Xavier Becerra is ordering Medicare to reassess a big premium increase facing millions of seniors this year
Les mer »
Medicare told to reassess premium hike for Alzheimer's drugHealth secretary orders Medicare to reassess a big premium increase facing millions of seniors this year, attributed in large part to a pricey new Alzheimer's drug with questionable benefits.
Les mer »
Medicare is about to make its most important coverage decision in years. Here’s how people with Alzheimer’s and others might be affected.A controversial new drug is roiling the medical community and driving up Medicare premiums.
Les mer »
Government May Scale Back Medicare Part B Premium IncreaseMedicare officials were instructed Monday to reassess the standard monthly amount due to a reduction in the cost of a drug that caused half the premium jump.
Les mer »